aTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Recommendation of “Hold” by Brokerages

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR) have been given a consensus rating of “Hold” by the eight brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $21.00.

A number of analysts have weighed in on the stock. Freedom Capital raised shares of aTyr Pharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 20th. Jefferies Financial Group reaffirmed a “buy” rating on shares of aTyr Pharma in a research report on Friday, March 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of aTyr Pharma in a research note on Friday, May 22nd. Finally, Wall Street Zen raised aTyr Pharma from a “sell” rating to a “hold” rating in a research report on Sunday, May 17th.

aTyr Pharma Price Performance

Shares of ATYR stock opened at $0.44 on Monday. aTyr Pharma has a 12 month low of $0.40 and a 12 month high of $7.29. The firm has a market cap of $43.18 million, a PE ratio of -0.60 and a beta of 0.55. The stock has a 50 day moving average of $0.67 and a 200-day moving average of $0.77.

aTyr Pharma (NASDAQ:ATYR) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.05. As a group, equities analysts predict that aTyr Pharma will post -0.66 EPS for the current fiscal year.

Insider Activity at aTyr Pharma

In other news, Director Paul Schimmel acquired 100,000 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The shares were bought at an average price of $0.50 per share, with a total value of $50,000.00. Following the acquisition, the director owned 779,143 shares of the company’s stock, valued at $389,571.50. This trade represents a 14.72% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.75% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System bought a new stake in aTyr Pharma in the 2nd quarter valued at $28,000. Legal & General Group Plc bought a new position in shares of aTyr Pharma during the 2nd quarter worth about $49,000. Prudential Financial Inc. acquired a new stake in shares of aTyr Pharma during the 2nd quarter valued at about $63,000. Oxford Asset Management LLP bought a new stake in aTyr Pharma in the second quarter valued at about $70,000. Finally, Creative Planning bought a new stake in aTyr Pharma in the second quarter valued at about $74,000. 61.72% of the stock is owned by institutional investors.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.